Over the last 7 days, the U.S. market has dropped 2.1%, though it remains up by 19% over the past year, with earnings forecast to grow by 17% annually. For investors interested in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer intriguing opportunities when they possess solid financial foundations and potential for growth. This article will explore several penny stocks that stand out for their financial strength and long-term potential.

Let's uncover some gems from our specialized screener.

Niagen Bioscience (NAGE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Niagen Bioscience, Inc. is a bioscience company focused on developing healthy aging products, with a market cap of $251.36 million.

Operations: The company's revenue is derived from Ingredients ($26.84 million), Consumer Products ($100.05 million), and Analytical Reference Standards and Services ($1.89 million).

Market Cap: $251.36M

Niagen Bioscience, Inc., with a market cap of US$251.36 million, shows promise in the penny stock realm through its strategic expansion into regulated drug development and healthy aging products. Recent earnings reveal a decline in net income to US$0.963 million for Q2 2026 from US$3.61 million the previous year, indicating challenges despite profitability over the past five years. The company has launched Tru Niagen® on Walmart.com, expanding consumer access to its NAD+ supplement line amid growing e-commerce trends. With no debt and seasoned management, Niagen's focus on NAD+ research positions it well for future growth opportunities in health sciences.

Nutriband (NTRB)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States and has a market cap of $43.15 million.

Operations: The company's revenue is primarily generated from its Pocono Pharmaceuticals segment, which accounts for $1.80 million.

Market Cap: $43.15M

Nutriband Inc., with a market cap of US$43.15 million, faces challenges typical of penny stocks, including limited revenue streams and ongoing unprofitability. Recent earnings for Q1 2026 show a decrease in sales to US$0.43 million from the previous year's US$0.67 million, alongside a net loss reduction to US$1.24 million. Despite these hurdles, the company has strengthened its financial position by securing a US$5 million credit line at 7% interest maturing in 2029 and maintains more cash than debt with short- and long-term liabilities well-covered by assets totaling US$4.4 million against liabilities of approximately $902K combined.

Definitive Healthcare (DH)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Definitive Healthcare Corp. offers a SaaS healthcare commercial intelligence platform both in the United States and internationally, with a market cap of $103.85 million.

Operations: The company's revenue is generated from its Internet Information Providers segment, totaling $232.70 million.

Market Cap: $103.85M

Definitive Healthcare Corp., with a market cap of US$103.85 million, operates in the SaaS healthcare sector but faces challenges typical of penny stocks, such as high volatility and ongoing unprofitability. Recent financial results show a decline in quarterly sales to US$55.2 million from US$60.75 million the previous year, with net losses narrowing slightly to US$5.42 million. The company has been removed from several major indices but added to the Russell Microcap Index, reflecting its current market position. Despite these hurdles, it maintains a strong cash runway exceeding three years and more cash than debt, suggesting some financial resilience amidst uncertainty over Nasdaq listing compliance due to its low share price.

Seize The Opportunity

• Jump into our full catalog of 318 US Penny Stocks here.
• Searching for a Fresh Perspective? Trump's oil boom is here — pipelines are primed to profit. Discover the 23 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.